Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Neoplasia (New York, N.Y.) - 1 Dec 2011

Vergani Elisabetta, Vallacchi Viviana, Frigerio Simona, Deho Paola, Mondellini Piera, Perego Paola, Cassinelli Giuliana, Lanzi Cinzia, Testi Maria Adele, Rivoltini Licia, Bongarzone Italia, Rodolfo Monica

Abstract excerpt

PLX4032/vemurafenib is a first-in-class small-molecule BRAF(V600E) inhibitor with clinical activity in patients with BRAF mutant melanoma. Nevertheless, drug resistance develops in treated patients, and strategies to overcome primary and acquired resistance are required. To explore the molecular mechanisms involved in primary resistance to PLX4032, we investigated its effects on cell proliferation and signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-met

Share to PTEN Phosphohydrolase

Share to src-Family Kinases

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 22241959
DOI: 10.1593/neo.111102
PMCID: PMC3257188

Genes

MET
BRAF
SRC
CCND1
CTNNB1
MITF
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.PMID 22241959Read ↗

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.Semantic proximity Read ↗

Multiple murine BRaf<sup>V600E</sup> melanoma cell lines with sensitivity to PLX4032Semantic proximity Read ↗

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.Semantic proximity Read ↗

Targeting BRAF in advanced melanoma: a first step toward manageable disease.Semantic proximity Read ↗

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.Semantic proximity Read ↗

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.Semantic proximity Read ↗

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Semantic proximity Read ↗

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Semantic proximity Read ↗

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.Semantic proximity Read ↗

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.